Ten Novel Mutations of the ADAR1 Gene in Japanese Patients with Dyschromatosis Symmetrica Hereditaria  by Suzuki, Noriyuki et al.
Ten Novel Mutations of the ADAR1 Gene
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Dyschromatosis symmetrica hereditaria (DSH) is a pigmentary genodermatosis of autosomal-dominant
inheritance. We have reported 20 different mutations of the adenosine deaminase acting on RNA 1 gene
(ADAR1) in patients with DSH since we had clarified that the disease is caused by a mutation of the ADAR1 gene
in 2003. In this study, we report 10 novel mutations responsible for DSH: p.Q102fsX123, p.T369fsX374,
p.S664fsX677, p.R892L, p.I913R, p.R916Q, p.P990fsX1016, p.C1081S, p.C1169F, and p.K1187X.
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INTRODUCTION
Dyschromatosis symmetrica hereditaria (DSH: MIM#127400)
shows an autosomal-dominant pattern of inheritance with
high penetrance. It is characterized by hyperpigmented and
hypopigmented macules on the face and dorsal aspects of the
extremities that appear in infancy or early childhood (Tomita
and Suzuki, 2004). In Asia, the condition occurs predomi-
nantly among Japanese and Chinese individuals (Oyama
et al., 1999). Miyamura et al. (2003) have clarified that a
heterozygous mutation of the adenosine deaminase acting on
RNA 1 (ADAR1 or DSRAD) gene causes DSH in four
Japanese DSH families. Subsequently, we reported 16 novel
mutations in the ADAR1 gene in Japanese patients with DSH
(Suzuki et al., 2005). On the other hand, 22 novel mutations
in the ADAR1 gene have been reported in Chinese and
Taiwanese patients with DSH (Chao et al., 2005; Cui et al.,
2005; Li et al., 2005a, b; Xing et al., 2005; Liu et al., 2006),
which confirmed that the ADAR1 gene is responsible for DSH
not only in Japanese but also in other ethnic groups.
ADAR1 protein catalyzes the deamination of adenosine to
inosine in double-stranded RNA substrates (Bass and
Weintraub, 1988; Wagner et al., 1989), which results in the
creation of alternative splicing sites or alternations of the
codon and thus leads to functional changes in the protein.
The ADAR1 gene is expressed ubiquitously, but the target
gene(s) in the skin still remain unknown, and also the
molecular pathogenesis of DSH has not been clarified yet.
In this study, we report 10 different novel mutations in
patients with DSH.
RESULTS AND DISCUSSION
Table 1 summarizes the clinical and molecular findings of
patients with DSH in this study.
We identified 10 novel heterozygous mutations containing
five missense mutations (p.R892L, p.I913R, p.R916Q, p.C1081S,
and p.C1169F), four frameshift mutations (p.Q102fsX123,
p.T369fsX374, p.S664fsX677, and p.P990fsX1016), and one
nonsense mutation (p.K1187X) in 10 patients (Table 1). One
sporadic and five families phenotypically presented typical
and strong macules on the dorsal aspects of the hands, feet,
lower arms, and lower legs, and freckle-like macules on the
face. The other four families showed faint phenotypes. No
relationship between the phenotypes and genotypes was
detected.
All of the five novel missense mutations identified in this
study (Table 1) were located at amino-acid residues
conserved among pufferfish, zebrafish, frog, rat, mouse,
cow, and human within the deaminase domain of the
ADAR1 protein. None of these five missense mutations was
found in the blood samples of any of the 100 unrelated,
normally pigmented Japanese adults who were surveyed.
Thus, we considered that these mutations should be the
pathogenic ones with no functional activity.
As shown in Table 1, all of the four frameshift mutations
and one nonsense mutation make a new stop codon after
each mutation, and ADAR1 protein synthesis should end
there without translating the full deaminase domain located
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in exons 9–15, which should produce inactive enzymes of
ADAR1.
So far, a total of 52 different mutations of the ADAR1 gene
have been reported in Japanese, Chinese, and Taiwanese
patients with DSH (Figure 1). Thirty-five mutations among the
fifty-two mutations (67%) are located within the deaminase
domain of the ADAR1 protein. The deaminase domain of the
ADAR1 protein is located in the codon from 886 to 1,221,
which is approximately 27% of the full length of the ADAR1
protein (Figure 1). These results suggest that the deaminase
domain might be a hot spot for mutations.
Human ADAR1 protein has been reported to include two
major forms; one is the IFN-inducible full-length 150-kDa
protein (hADAR1-p150) and the other is the constitutively
expressed N-terminally truncated 110-kDa protein (hADAR1-
p110). The production of the two forms is due to the presence
of different promoters (Kawakubo and Samuel, 2000). The
methionine initiation codon for the 1,226-amino-acid open
reading frame specifies the hADAR1-p150. On the other
hand, the AUG at codon 296 initiates translation of the 931-
amino-acid open reading frame encoding the hADAR1-p110.
The two mutations of p.Q102fs reported in this study and
p.H216fs reported previously (Suzuki et al., 2005) are located
at the 50 side of codon 296 which is the translation initiation
codon for hADAR1-p110 (Figure 1). Therefore, they must
cause frameshift changes in the synthesis of hADAR1-p150,
Table 1. Novel mutations of the ADAR1 gene
Patient’s pedigree Mutation Phenotype
Patient No.1 Incidence
Affected
individuals
Unaffected
individuals Nucleotide change2
Amino-acid
change Exon Onset Degree
23 Familial 2 2 c.1105–1106insA p.T369fsX374 Ex2 2 years Faint
24 Sporadic 1 — c.3559A4T p.K1187X Ex15 2–3 years Strong
25 Familial 7 3 c.2738T4G p.I913R Ex9 1 year Strong
26 Familial 4 3 c.2747G4A p.R916Q Ex9 2 years Faint
27 Familial 3 5 c.305–306delAG p.Q102fsX123 Ex2 Childhood Faint
28 Familial 5 5 c.3506G4T p.C1169F Ex15 Childhood Strong
29 Familial 4 1 c.2675G4T p.R892L Ex9 Childhood Strong
30 Familial 2 1 c.3241T4A p.C1081S Ex13 1 year Strong
31 Familial 3 5 c.1991delG p.S664fsX677 Ex5 1 year Faint
32 Familial 3 4 c.2969–2970delCT p.P990fsX1016 Ex11 1–2 years Strong
1A serial number of patients in our group.
2GenBank accession no. NM_001111.3. Position 1 is A of the translation initiation codon.
hADAR1-p150 hADAR1-p110
Q102fs H216fs
Q513X Q933X
K952X
Q600X
G507fs
R474X
K433fs
R426X
T369fs
C519fs
IVS2+2T>G
IVS8+2T>A IVS12-2A>G
G882fs
T811fs
L792fs
P727fs
E733X
S664fs
V955fs
V977fs
L1057fs
P990fs
G1073fs
R1096X
R1171fs
Y1112fs
K1187X
K1201fs
DeaminasedsRBD
dsR
BD
dsR
BDZZ
R892L
V906F
I913R
R916Q
R916W
L923P
Y960C
C966F
K1003R
K1007R
C1036S
K1039R
S1064F
H1075R
R1078C
R1083C
C1130R
R1155W
F1165S
C1081S
C1169F
Figure 1. Mutations of the ADAR1 gene reported in patients with DSH. Mutations above the horizontal axis are nonsense, frameshift, and splicing mutations;
those below are missense mutations. The shadowed ones indicate the new mutations identified in this study. Za and Zb, Z-DNA-binding domains;
dsRBD, double-stranded RNA-binding domains; deaminase, deaminase domain.
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but an effect on the synthesis of p110 protein is not obvious.
Further analysis, such as a stability assay on the p110 mRNA
including the mutations, should be carried out for definitive
assignment of mutation functionality.
MATERIALS AND METHODS
Subjects
A total of 10 unrelated Japanese patients with DSH and 100 unrelated,
normally pigmented Japanese were included in the mutation analysis.
One patient (no. 24) with DSH had no family history of the disease and
the families of the other patients turned out to have at least one other
affected individual in each family (Table 1). We screened one affected
individual of each pedigree for a mutation of the ADAR1 gene. The
birthplaces of the patients were scattered around Japan, and no high
incidence area for DSH was found. The patients originally consulted us
for their skin conditions. The degree of hyper- and hypopigmentation in
each patient varied from distinct to indistinct. This study was approved
by the Ethics Committee of Nagoya University Graduate School of
Medicine. This study was conducted according to the Declaration of
Helsinki Principles. Informed written consent was obtained from each
patient or from the patient’s parents in the case of children.
Mutation detection and conformation
Mutation analysis of the ADAR1 gene was performed as described
previously (Suzuki et al., 2004, 2005). Briefly, genomic DNA was
extracted from peripheral blood samples. The mutation screening
was carried out with single-strand conformation polymorphism/
heteroduplex analysis and direct sequencing. ADAR1 GenBank
sequences used: NM_001111.3 (cDNA).
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